See more : Hon Hai Precision Industry Co., Ltd. (2317.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Jaguar Health, Inc. (JAGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jaguar Health, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Vitro, S.A.B. de C.V. (VITROA.MX) Income Statement Analysis – Financial Results
- Dawning Information Industry Co., Ltd. (603019.SS) Income Statement Analysis – Financial Results
- Ni Steel Co.,Ltd (008260.KS) Income Statement Analysis – Financial Results
- Kuei Tien Cultural & Creative Entertainment (4806.TWO) Income Statement Analysis – Financial Results
- Ubiqconn Technology, Inc. (6928.TW) Income Statement Analysis – Financial Results
Jaguar Health, Inc. (JAGX)
About Jaguar Health, Inc.
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.76M | 11.96M | 4.34M | 9.39M | 5.78M | 4.42M | 4.36M | 141.52K | 258.38K | 0.00 |
| Cost of Revenue | 2.04M | 2.02M | 2.33M | 3.28M | 3.82M | 2.77M | 880.41K | 51.97K | 123.46K | 0.00 |
| Gross Profit | 7.72M | 9.94M | 2.00M | 6.11M | 1.96M | 1.65M | 3.48M | 89.56K | 134.92K | 0.00 |
| Gross Profit Ratio | 79.13% | 83.11% | 46.18% | 65.05% | 33.93% | 37.37% | 79.81% | 63.28% | 52.22% | 0.00% |
| Research & Development | 18.60M | 17.65M | 15.08M | 6.41M | 5.82M | 5.15M | 4.27M | 7.21M | 6.48M | 4.22M |
| General & Administrative | 16.59M | 17.87M | 17.10M | 14.39M | 13.50M | 12.28M | 11.25M | 5.98M | 5.34M | 0.00 |
| Selling & Marketing | 6.46M | 8.84M | 8.89M | 6.61M | 6.94M | 9.83M | 3.08M | 485.44K | 765.09K | 0.00 |
| SG&A | 23.05M | 26.71M | 26.00M | 21.00M | 20.44M | 22.11M | 14.33M | 6.47M | 6.10M | 4.10M |
| Other Expenses | 371.00K | 950.00K | -765.00K | 190.00K | 648.80K | 315.69K | 88.55K | -11.05K | -27.28K | 0.00 |
| Operating Expenses | 42.02M | 44.35M | 41.08M | 27.41M | 26.91M | 27.26M | 18.60M | 13.68M | 12.58M | 8.32M |
| Cost & Expenses | 44.05M | 46.37M | 43.41M | 30.69M | 30.72M | 30.03M | 19.48M | 13.73M | 12.70M | 8.32M |
| Interest Income | 0.00 | 12.72M | 8.42M | 2.79M | 5.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.38M | 12.72M | 8.42M | 2.79M | 5.73M | 2.63M | 1.21M | 985.55K | 3.32M | 0.00 |
| Depreciation & Amortization | 1.16M | 2.29M | 1.83M | 2.28M | 1.93M | 1.75M | 584.34K | 47.49K | 5.16K | -51.42K |
| EBITDA | -33.13M | -33.38M | -42.35M | -28.74M | -30.87M | -27.77M | -11.13M | -13.70M | -12.97M | -8.37M |
| EBITDA Ratio | -339.42% | -260.73% | -914.88% | -257.61% | -397.20% | -454.56% | 100.27% | -9,459.45% | -4,620.54% | 0.00% |
| Operating Income | -34.29M | -34.42M | -39.07M | -21.30M | -24.95M | -30.82M | -34.25M | -13.59M | -12.45M | -8.32M |
| Operating Income Ratio | -351.31% | -287.85% | -901.36% | -227.00% | -431.98% | -697.98% | -785.27% | -9,599.84% | -4,816.67% | 0.00% |
| Total Other Income/Expenses | -7.61M | -13.98M | -11.89M | -7.16M | -9.58M | -1.32M | -902.80K | -1.15M | -3.85M | -293.91K |
| Income Before Tax | -41.90M | -48.40M | -52.60M | -33.81M | -38.53M | -32.15M | -35.15M | -14.73M | -16.29M | -8.61M |
| Income Before Tax Ratio | -429.27% | -404.78% | -1,213.38% | -360.25% | -667.15% | -727.92% | -805.97% | -10,410.87% | -6,305.24% | 0.00% |
| Income Tax Expense | 0.00 | -941.00K | 7.65M | 2.98M | 10.00K | -1.28M | -13.18M | 1.14M | 3.82M | 345.34K |
| Net Income | -41.30M | -47.45M | -60.25M | -36.79M | -38.54M | -32.15M | -21.97M | -14.73M | -16.29M | -8.61M |
| Net Income Ratio | -423.11% | -396.91% | -1,389.87% | -392.02% | -667.32% | -727.92% | -503.73% | -10,410.87% | -6,305.24% | 0.00% |
| EPS | -107.42 | -36.18 | -101.07 | -214.22 | -1.75K | -15.51K | -27.26K | -249.73K | -479.16K | -204.99K |
| EPS Diluted | -107.42 | -36.18 | -101.07 | -214.22 | -1.75K | -15.51K | -27.26K | -249.73K | -479.16K | -204.99K |
| Weighted Avg Shares Out | 384.47K | 1.31M | 596.15K | 171.75K | 22.07K | 2.07K | 806.00 | 59.00 | 34.00 | 42.00 |
| Weighted Avg Shares Out (Dil) | 384.47K | 1.31M | 596.15K | 171.75K | 22.07K | 2.07K | 806.00 | 59.00 | 34.00 | 42.00 |
Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea
Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae Crofelemer previously granted Orphan Drug Designation by the FDA and the EMA for both short bowel syndrome and microvillus inclusion disease SAN FRANCISCO,...
Jaguar Health to Present January 31 at The Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select Conference
SAN FRANCISCO, CA / ACCESSWIRE / January 29, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on January 31, 2024 at The Microcap Conference in Atlantic City,...
Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health's Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD)
This study, conducted by Jaguar family company Napo Pharmaceuticals in collaboration with Puma Biotechnology, is one of three important studies providing scientific rationale for the use of crofelemer for prevention and treatment of CTD Studies published in peer-reviewed journals and...
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / January 5, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective January 4, 2024, the Company granted 7,500 restricted stock units (RSUs) to one new employee. These RSUs vest...
Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
New patent issued for core rare disease target indication for crofelemer Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of microvillus inclusion disease - an ultrarare CDD - and short bowel syndrome (SBS) in the...
A Majority of Subjects in Jaguar Health's Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage II
Stage II completed; comprehensive results expected in Q1 2024; company's planned regulatory pathway for FDA approval remains on track Cancer patients at patient advocacy events voice strong support for company's focus on patient quality of life and the highly neglected...
MASCC (Multinational Association of Supportive Care in Cancer) Webinar on GI Toxicities from Cancer Therapies Made Possible by Grant From Napo Pharmaceuticals, a Jaguar Health Family Company
To register for the webinar, click here SAN FRANCISCO, CA / ACCESSWIRE / December 7, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that a Multinational Association of Supportive Care in Cancer (MASCC) webinar...
Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website
SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the abstract for "More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis...
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs
Canalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA Crofelemer, Jaguar's novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, is the active ingredient in...
Jaguar Health to Present December 5 at the MedInvest Oncology Investor Conference
Top line data for Jaguar Health's pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy forthcoming SAN FRANCISCO, CA / ACCESSWIRE / November 30, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today...
Source: https://incomestatements.info
Category: Stock Reports